

SPECIAL eBULLETIN

FOR PROFESSIONAL AND FACILITY PROVIDERS

JUNE 17, 2022

DELAYED: AUTHORIZATIONS WILL SOON BE REQUIRED FOR OUT-OF-AREA AND OUT-OF-NETWORK MUSCULOSKELETAL, GENETIC TESTING, AND RADIATION ONCOLOGY SERVICES

On April 29, 2022, Highmark [announced](#) that beginning August 1, 2022, authorizations are going to be required for out-of-area and out-of-network musculoskeletal, genetic testing, and radiation oncology services managed by eviCore. **This has been delayed and authorizations for these out-of-area and out-of-network services will not be required on August 1, 2022, as planned.**

Highmark will communicate the new go-live date via an eBulletin on the Provider Resource Center once a new date has been determined.

For more information on this change, please review the [AUTHORIZATIONS WILL SOON BE REQUIRED FOR OUT-OF-AREA AND OUT-OF-NETWORK MUSCULOSKELETAL, GENETIC TESTING, AND RADIATION ONCOLOGY SERVICES](#) eBulletin.



This information is issued on behalf of Highmark Blue Shield and its affiliated Blue companies, which are independent licensees of the Blue Cross Blue Shield Association. Highmark Inc. d/b/a Highmark Blue Shield and certain of its affiliated Blue companies serve Blue Shield members in 21 counties in central Pennsylvania and 13 counties in northeastern New York. As a partner in joint operating agreements, Highmark Blue Shield also provides services in conjunction with a separate health plan in southeastern Pennsylvania. Highmark Inc. or certain of its affiliated Blue companies also serve Blue Cross Blue Shield members in 29 counties in western Pennsylvania, 13 counties in northeastern Pennsylvania, the state of West Virginia plus Washington County, Ohio, the state of Delaware and 8 counties in western New York. All references to Highmark in this document are references to Highmark Inc. d/b/a Highmark Blue Shield and/or to one or more of its affiliated Blue companies.